Westchester Medical Center and BioGenCell Open BioGenCell's Fourth Chronic Limb-Threatening Ischemia Clinical Trial Site in the United States
NEW YORK, Sept. 5, 2023 /PRNewswire/ -- BioGenCell, a leader in personalized cell therapy solutions and Westchester Medical Center, the academic affiliate of Touro University/New York Medical College have announced the launch of BioGenCell's fourth Phase II clinical trial site in the United States. The trial targets a considerable reduction in the need for amputation in patients with chronic limb-threatening ischemia (CLTI, also known as CLI). Westchester Medical Center, the flagship hospital in the Westchester Medical Center Health Network (WMCHealth) joins an ambitious, global, placebo-controlled trial aimed at delivering life-altering positive outcomes for patients.
- Westchester Medical Center (an academic affiliate of Touro University/New York Medical College) and BioGenCell have marked a milestone with the opening of a Phase II cell-therapy based clinical trial site for Chronic Limb-Threatening Ischemia (CLTI) in the United States, following Yale University New Haven Hospital, John Hopkins University, and UCSF.
- NEW YORK, Sept. 5, 2023 /PRNewswire/ -- BioGenCell, a leader in personalized cell therapy solutions and Westchester Medical Center, the academic affiliate of Touro University/New York Medical College have announced the launch of BioGenCell's fourth Phase II clinical trial site in the United States.
- The trial targets a considerable reduction in the need for amputation in patients with chronic limb-threatening ischemia (CLTI, also known as CLI).
- Westchester Medical Center, the flagship hospital in the Westchester Medical Center Health Network (WMCHealth) joins an ambitious, global, placebo-controlled trial aimed at delivering life-altering positive outcomes for patients.